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Abstract
Background: Resistance of high-risk metastatic neuroblastoma (HR-NB) to high dose chemotherapy
(HD-CT) raises a major therapeutic challenge in pediatric oncology. Patients are treated by maintenance
CT. For some patients, an adjuvant retinoid therapy is proposed, such as the synthetic retinoid fenretinide
(4-HPR), an apoptotic inducer. Recent studies demonstrated that NB metastasis process is enhanced by
the loss of caspase-8 involved in the Integrin-Mediated Death (IMD) process. As the role of caspase-8
appears to be critical in preventing metastasis, we aimed at studying the effect of 4-HPR on caspase-8
expression in metastatic neuroblasts.
Methods: We used the human IGR-N-91 MYCN-amplified NB experimental model, able to disseminate
in vivo from the primary nude mouse tumor xenograft (PTX) into myocardium (Myoc) and bone marrow
(BM) of the animal. NB cell lines, i.e., IGR-N-91 and SH-EP, were treated with various doses of Fenretinide
(4-HPR), then cytotoxicity was analyzed by MTS proliferation assay, apoptosis by the propidium staining
method, gene or protein expressions by RT-PCR and immunoblotting and caspases activity by colorimetric
protease assays.
Results: The IGR-N-91 parental cells do not express detectable caspase-8. However the PTX cells
established from the primary tumor in the mouse, are caspase-8 positive. In contrast, metastatic BM and
Myoc cells show a clear down-regulation of the caspase-8 expression. In parallel, the caspases -3, -9, -10,
Bcl-2, or Bax expressions were unchanged. Our data show that in BM, compared to PTX cells, 4-HPR up-
regulates caspase-8 expression that parallels a higher sensitivity to apoptotic cell death. Stable caspase-8-
silenced SH-EP cells appear more resistant to 4-HPR-induced cell death compared to control SH-EP cells.
Moreover, 4-HPR synergizes with drugs since apoptosis is restored in VP16- or TRAIL-resistant-BM cells.
These results demonstrate that 4-HPR in up-regulating caspase-8 expression, restores and induces
apoptotic cell death in metastatic neuroblasts through caspase-8 activation.
Conclusion: This study provides basic clues for using fenretinide in clinical treatment of HR-NB patients.
Moreover, since 4-HPR induces cell death in caspase-8 negative NB, it also challenges the concept of
including 4-HPR in the induction of CT of these patients.
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Neuroblastoma (NB), the second most common solid
tumour in children, is an embryonic malignancy which
originates from sympathetic neurons. Whereas localized
tumors in young infants often spontaneously regress or
mature in response to treatments, the outcome of high-
risk NB, incurable in 60% of cases, remains poor and
poses a major therapeutic challenge in pediatric oncology
[1]. Apoptosis or programmed cell death is believed to
represent an essential mechanism of drug-mediated toxic-
ity [2]. Recent studies highlight the role of apoptosis in the
metastatic process showing that defects in the apoptosis
program contributed not only to malignancy or drug
resistance but also to metastasis. Indeed, apoptosis is
nowadays considered as a central mechanism in the devel-
opment of metastases [3].
Apoptosis is an extremely well-organized process mediated
by the caspases protein family. Upon activation by proteo-
lytic cleavage, effector caspases cleave their substrates and
inactivate proteins essential for survival, leading to the dis-
integration of cells [4]. The caspase-8 is a key enzyme at the
top of the apoptotic cascade, both involved in the extrinsic
or death receptors pathway and in the intrinsic mitochon-
drial pathway. Several studies have reported that the cas-
pase-8 gene was frequently inactivated by
hypermethylation in NB cell lines [5-7], alterations mainly
described in aggressive and amplified MYCN high-stage
tumors. However, no correlation has been established
between caspase-8 expression and MYCN amplification or
aggressive disease criteria [8]. Despite caspase-8 status is
not predictive of aggressive NB, recent findings suggest that
caspase-8 loss contributes to a metastatic phenotype, thus
defining caspase-8 as a metastasis suppressor gene for NB
[9]. The authors demonstrated that NB metastasis process is
enhanced by the simultaneous loss of caspase-8 and of
α3β1 integrin which subsequently impairs integrin-medi-
ated death (IMD) to occur [10]. Therefore, caspase-8
appears as an attractive target to reduce the formation of NB
metastases [11]. Among the numerous approaches manip-
ulating caspase-8 levels, therapeutic strategies have used
agents such as 5-Azacytidine [6], IFN-γ [12,13], IFN-γ asso-
ciated with 5-Azacytidine [14], or the synthetic retinoid
Fenretinide N-(4-hydroxyphenyl) retinamide/4-HPR [15].
Interestingly, 4-HPR has been reported to inhibit the inva-
sion of several cancer cell types, including breast cancer,
ovarian, prostate cancer and Kaposi's sarcoma, and NB
[16]. Identified to induce apoptosis in various cell lines, the
reagent 4-HPR-, -unlike retinoic acid (RA)-, -is more effec-
tive to induce apoptosis than differentiation in NB and
proved a good efficacy against NB cell lines which are resist-
ant to RA [17,18]. Moreover, 4-HPR is clinically well toler-
ated and used for clinical trials in neuroblastoma [19,20].
Our previous studies, performed in the experimental IGR-
N-91 human MYCN-amplified model, reported the main
involvement of P-gp/MDR in the chemoresistance of met-
astatic neuroblasts [21,22]. In this NB xenograft model,
the IGR-N-91 neuroblasts have disseminated in vivo from
the primary nude mouse tumor xenograft (PTX) into
myocardium (Myoc) and bone marrow (BM) of the ani-
mal. Given the recent findings of i) potentiation of NB
metastasis by loss of caspase-8 in a murine model and ii)
halting NB metastasis by controlling IMD in the same
model, we have investigated the expression of caspase-8
in metastatic neuroblasts of this experimental model. As
we have observed a specific loss of caspase-8 expression in
metastases, we therefore decided to restore caspase-8
activity with 4-HPR and to study its apoptotic-inducing
effect in metastatic neuroblasts. Moreover, we have inves-
tigated the putative synergic effect of 4-HPR with cytotoxic
drug- or TRAIL-mediated apoptosis in chemoresistant
metastatic neuroblasts. Our results provide evidence that
4-HPR enhances cell death in caspase-8 deficient meta-
static malignant neuroblasts and thus may be combined
with toxic agents to an increased efficacy in the treatment
of high-risk metastatic NB.
Methods
Cell culture and reagents
NB cell lines include the N-type NB IGR-N-91 cells and the
S-type NB cells SH-EP. The IGR-N-91 cell line was estab-
lished from a stage-4 NB infiltrated bone marrow [21].
Human IGR-N-91 NB cells were injected subcutaneously
into nude mice: a primary tumor xenograft cell line (PTX),
blood cells (BC), myocardium (Myoc) and bone marrow
(BM) sub-lines were obtained from mechanically dissoci-
ated tumor samples and were grown as previously
described [21,22]. Each cell line was cultured in Dulbecco's
Modified Eagle Medium (DMEM) supplemented with 2
mM L-glutamine, 10 μg/ml gentamycin and 10% fetal calf
serum, at 37°C in a 5% CO2 humidified atmosphere.
4-HPR (from Sigma-Aldrich, Germany) was dissolved in
ETOH. Throughout this study, we used 1–10 μM of 4-HPR
for the N-type NB cells and 1–20 μM for the S-type NB cells.
The concentrations were sufficient to induce cell death in
NB cells as determined previously [23,24]. Cells were
treated with 20–40 μM etoposide (VP16) (Sigma, St Louis,
MO), both dissolved in DMSO, for 24 or 48 hours. An
equal volume of vehicle control (DMSO) was used to treat
control cells. Cells were incubated with indicated amount
of soluble recombinant TRAIL (a gift from J. Tschopp) and
cross-linking anti-Flag Ab M2 (Sigma) with a constant ratio
of 1/5 of TRAIL/M2 as previously described [25]. Cells were
pretreated with caspase inhibitors zIETD-fmk, zDEVD-fmk,
zVDAVD-fmk and zLEHD-fmk (50 μM, R&D systems SA,
Switzerland) before drug treatment.
Tumor growth
Athymic locally bred Swiss nude mice were engrafted with
the IGR-N-91 cell line, in accordance to the EuropeanPage 2 of 13
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Mice (n = 4) were anaesthetized using ketamine 50 mg/kg
and xylazine 35 mg/kg intraperitoneally (I.P.). Hetero-
topic tumors were obtained by subcutaneous injection in
the back of the animal of 1 × 106 NB cells suspended in
200 ml of Matrigel® (BD Biosciences, San Diego, CA)
using a 22 G needle connected to a 1-ml syringe. After
recovery, the animals were kept in a germ-free protected
area, with food ad libitum. Mice were sacrificed after 2
months. Tumors were resected and dissociated as
described previously [26]. Proteins were isolated using
lysis buffer as described above.
Retroviral infection experiments
IGR-N-91 cells were infected with a biscistronic retroviral
vector encoding for the GFP and the caspase-8a genes (IGR-
N91-C8) or with the GFP control vector (IGR-N91-M) as
described previously [25]. One clone was respectively cho-
sen among the GFP positive IGR-N91-M clones and among
the IGR-N91-C8 clones, then assessed to control the expres-
sion level of caspase-8 by immunoblotting. Stable down-
regulation of caspase-8 was achieved by RNA interference
using short hairpin RNAs [27]. Different splice variants of
caspases-8 mRNA were identified leading to the production
of diverse C8 isoforms [28]. To efficiently silence all caspase
isoforms, the shRNAs have been localized in common
exons and correspond to the sequence 5'-AAGTTCCT-
GAGCCTGGACTAC-3' as proposed previously [29]. The
sequence of oligonucleotides encoding the control random
shRNA (shRNAC) is 5'-CGATTGCGATCGTCAATTCCC-3'
[30]. The sequences were checked by sequencing a PCR-
amplified region containing the oligonucleotide and shR-
NAs were prepared and used to infect the SH-EP cell line as
already described [30].
Cell viability and apoptosis assays
Cell viability was measured using the MTS/PMS cell pro-
liferation kit from Promega (France) according the manu-
facturer's instructions. 105 cells were seeded 24 hours into
a 96-well plate containing 100 μl of medium, then incu-
bated with 4-HRP or drugs for 24 or 48 hours. Assays were
performed in quadruplicates. Percentage of cell viability/
cell death was determined as compared to untreated con-
trols. Apoptosis was evaluated using the standard PI-stain-
ing protocol. Cells were trypsinized and neutralized in
complete medium, washed twice with 3 ml PBS. Cell pel-
lets were resuspended in 1 ml of PBS on ice then fixed in
3 ml of 100% ethanol. After fixation, pellets were kept at
-20°C. Cells were stained in PI solution (50 μg/ml PI, 100
μg/ml RNAseA in PBS) for 30 min at room temperature.
The stained cells were analyzed using a FACScan flow
cytometer (Becton Dickinson, France SAS).
Caspase-8 expression in the IGR-N-91 experimental metastatic modelFigure 1
Caspase-8 expression in the IGR-N-91 experimental metastatic model. A) Western Blot analyses of caspases-3, -8, -
9, Bcl-2 and Bax expressions in cell lines of the IGR-N-91 experimental model. Semi-quantitative RT-PCR analyses of caspase-8 
mRNA expressions and GAPDH as internal control. PTX: Primary Tumor Xenograft, BM: Bone Marrow, Myoc: Myocardium. 
B) Whole extracts from the IGR-N-91 and SH-EP cell lines, and four IGR-N-91 primary tumor xenografts were analyzed by 
immunoblotting for caspase-8 expression. β-actin was used as loading control.
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Western blots were performed on cultured cells homoge-
nized in RIPA buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1% NP40, 0.5% DOC, 0.1% SDS) on ice for 15
minutes. Protein extracts (50 μg/lane) were loaded on 10–
12% SDS-PAGE, transferred on nitrocellulose mem-
branes. Immunoblots were saturated with 5% skim milk,
0.1% Tween-20 in TBS and revealed using mouse mono-
clonal antibodies or rabbit polyclonal antibodies to detect
Bcl-2 (C124, Dako France), Bax (BD Pharmingen Inc., San
Diego, USA), procaspase-3 (BD Pharmingen), procaspase-
8 (MBL International, USA), procaspase-9 (Cell Signaling
Technology, Inc., USA), procaspase-10 (MBL Interna-
tional), β-actin (Sigma). Bound antibodies were revealed
by incubation with either goat anti-mouse IgG (Jackson
ImmunoResearch Laboratories, Inc., Europe) or goat anti-
rabbit IgG (Nordic Immunological Laboratories, Nether-
lands), and subsequently detected using the Lumilight
Western Blotting substrate (Roche Diagnostics, Switzer-
land,) according to the manufacturer's instructions.
Caspases activities
Caspases-3, -8, and -9 protease activities were measured
using the caspase colorimetric protease assay kits from MBL
Co., Ltd, USA as previously described [25]. Cytosolic lysates
were prepared 24 or 48 hrs after 4-HPR treatment according
to manufacturer's instructions. 100 μg protein extracts were
incubated with 200 μM of DEVD-pNA, IETD-pNA, Ac-
LEDH-pNA colorimetric substrates for 3 hrs at 37C. Cell
lysates were incubated with 10 μM of caspase inhibitor
(zDEVD-fmk, zIETD-fmk, zLEDH-fmk) for 30 min before
addition of the respective caspase substrates for control
experiments. Hydrolyzed pNA was detected using a micro-
titer plate reader at 405 nm. Background absorbance from
cell lysates and buffers were subtracted from the absorb-
ance of stimulated and unstimulated samples before calcu-
lation of relative caspases activities.
RT-PCR experiments
Total RNA was isolated using RNAble reagent (Eurobio,
France). Reverse transcription was performed from 1 μg total
RNA using Superscript II RNase H-Reverse Transcriptase
(Gibco BRL). PCR reactions were performed on 1 ng of
cDNA using the Platinum Taq polymerase (Invitrogen Cor-
poration, Switzerland) in a PTC100 thermocycler (MJ
Research, Inc., USA). The sequences of primers used were as
follows: for caspase-8 (forward: 5'-TCTGGAGCATCTGCT-
GTCTG-3'; reverse: 5'-CCTGCCTGGTGTCTGAAGTT-5') and
for GAPDH (forward: 5'-CTGCACCAACTGCTTAG-3',
reverse: 5'-AGGTCCACCACTGACACGTT-3'). The PCR
products were analyzed by 1.5% agarose gel electrophoresis.
The size of PCR fragment is 356 bp.
Statistical Analysis
Results are shown as the mean ± SD of at least three exper-
iments each. Data were analyzed using the Student's t test
with P values of <0.05 (*) or <0.01 (**) considered to rep-
resent significance.
Results
Loss of caspase-8 expression in metastatic neuroblasts
We have first analyzed caspase-8 expression level in PTX,
BM and Myoc cell lines of the IGR-N-91 experimental
model (Figure 1A). We observed that the IGR-N-91 cell
line is caspase-8-negative. Surprisingly, caspase-8 expres-
sion is restored in PTX compared to parental IGR-N-91
neuroblasts, then downregulated in BM or Myoc meta-
static neuroblasts. RNA analysis revealed caspase-8 mRNA
transcripts in parental IGR-N-91 cells as well as in Myoc
neuroblasts while totally absent in BM cells (Figure 1A).
In contrast, no change was observed in the expression lev-
els of caspases-3, -9 as well as Bcl-2 and Bax. Therefore, we
examined by immunoblotting caspase-8 expression level
in four primary tumors xenografts of mouse engrafted
with IGR-N-91 neuroblasts (Figure 1B). The SH-EP cell
line was used as a caspase-8-positive control cell line. As
for PTX neuroblasts, caspase-8 expression is fully restored
in the four primary tumors.
4-HPR induced re-expression of caspase-8 and apoptotic 
cell death in BM metastatic neuroblasts
As the role of caspase-8 appears critical in preventing
metastasis, we aimed at studying the effect of the retinoid
4-HPR on caspase-8 expression. Figure 2 shows a specific
up-regulation of the caspase-8 protein level in BM meta-
static neuroblasts treated with 2.5 or 5 μM 4-HPR for 72
hours, while no change was observed in PTX cells. No
change was noted in the levels of caspase-3, -9, -10 and
Bcl-2 expressions in PTX or BM neuroblasts. Additionally,
MTS analysis was performed in PTX and BM neuroblasts
4-HPR induces caspase-8 expression in BM metastatic neu-roblastsFigure 2
4-HPR induces caspase-8 expression in BM meta-
static neuroblasts. Western Blotting of caspases-3, -8, -9, -
10 and Bcl-2 expressions in PTX and BM neuroblasts treated 
with 2.5 or 5 μM 4-HPR.
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that PTX cells are more resistant to cell death than BM cells
(Figure 3A). Indeed, 4-HPR-induced cell death is dose-
and time-dependent (Figure 3A, B). As 4-HPR has been
previously described to induce apoptotic cell death in
neuroblastoma cell lines [23], we have compared the
extent of 4-HPR-mediated apoptosis in PTX and BM neu-
roblasts. FACS analysis shows that apoptosis was signifi-
cantly increased in BM neuroblasts, whereas no apoptosis
occurred in PTX cells (Figure 3C). Thus, the increase of the
caspase-8 expression appears correlated with a higher sen-
sitivity of apoptotic cell death in BM compared with PTX
neuroblasts.
Caspase-8 activation by 4-HPR in BM metastatic 
neuroblasts
In order to analyze the involvement of caspase-8 in cell-
death execution, we conducted studies using specific inhib-
itors. The 4HPR-induced cell death is not significantly
blocked in PTX cells by zDEVD-fmk (a caspase-3 inhibitor),
zIETD-fmk (a caspase-8 inhibitor), or zLEHD-fmk (a cas-
pase-9 inhibitor) (Figure 4A). In contrast, we observed that
4HPR-induced cell death can be blocked by zIETD-fmk (P
< 0.01), more partially by zLEDH-fmk (P < 0.01) and
slightly by zVDAVD-fmk (a caspase-2 inhibitor) (P < 0.05)
in BM cells. However, no inhibition of cell death was noted
with the caspase-3 inhibitor zDEVD-fmk (Figure 4B). The
4-HPR induces apoptosis in BM metastatic neuroblastsFigure 3
4-HPR induces apoptosis in BM metastatic neuroblasts. A-B) Dose-response and time-course analysis of 4-HPR-
induced cell death in PTX and BM neuroblasts. Cell viabilities assessed by MTS analysis in PTX and BM neuroblasts treated with 
5 or 10 μM 4-HPR for 48 hours (A) or with 10 μM 4-HPR for 1 to 4 days (B). The values reported are mean ± SD of three 
independent experiments. ** P < 0.01 indicates difference between PTX and BM neuroblasts. C) The increase of apoptotic cell 
death is correlated with caspase-8 re-expression in BM metastatic cells. Sub-G1 apoptotic cells were detected by the propid-
ium staining method after stimulation for 72 hours with 2.5 or 5 μM 4-HPR. Mean values ± SD of 3 independent experiments 
are shown.** P< 0.01 indicates significant difference between PTX/BM cells and respective untreated cells.
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static cells incubated with 10 μM 4-HPR for 24 or 48 hours.
A slight increase of caspase-8 activity is noted within 24 hrs,
appears more sustained after 48 hours, and is reduced by
the caspase-8 inhibitor zIETD-fmk (Figure 4C). However,
no significant variation of caspases-3 or -9 activities was evi-
denced in these conditions (data not shown).
Caspase-8 negative NB cell lines are resistant to 4-HPR-
induced cell death
To corroborate the specific contribution of caspase-8 in 4-
HPR-induced apoptosis, we have used the caspase-8-defi-
cient NB cell line (IGR-N91-M) and the stably restored
caspase-8 cell line (IGR-N91-C8) previously described
[25]. We observed that the treatment of 2.5 or 5 μM 4-
HPR strongly up-regulated caspase-8 expression in the
IGR-N91-M neuroblasts, while no change was observed in
the IGR-N91-C8 cells (Figure 5A). In parallel, significant
cell death may be noted both in 4HPR-treated IGR91-M
and IGR91-C8 neuroblasts (Figure 5B). Thus, the increase
of caspase-8 expression may be correlated with the higher
cell death sensitivity noted in the 4HPR-incubated IGR91-
M cells compared with control.
To extend the observation that caspase-8 activation plays
a major role in 4-HPR-induced cell death, we examined
the response of SH-EP cell line to 4-HPR, after silencing of
caspase-8 expression. SH-EP cells were stably transfected
with shRNAs against caspase-8 (SHEP-shC8) and non-
silencing control (SHEP-nsc). As expected, western blot
analysis shows that caspase-8 is silenced in SHEP-shC8
(Figure 6A). The two cell lines were then treated with
increasing doses of 5, 10 or 15 μM 4-HPR for 48 hours.
The 4HPR treatment did not change caspase-8 expression
neither in SHEP-nsc or SHEP-shC8 cells (Figure 4B). Cell
death was measured using the MTS test (Figure 6B). Inter-
Caspase-8 activation in BM metastatic neuroblastsFigure 4
Caspase-8 activation in BM metastatic neuroblasts. A-B) Cell viabilities assessed by MTS analysis in PTX cells (A) and 
in BM cells (B) pretreated with 50 μM of caspase inhibitor (zVDAVD-fmk, zIETD-fmk, zLEHD-fmk, zDEVD-fmk) for 1 hr, then 
treated with 10 μM 4HPR for 48 hrs. Data points show mean ± SD of 3 independent experiments. *P < 0.05, **P < 0.01 com-
pared with control cells treated with 4-HPR only. C) Caspase-8 activity was measured using lysates from BM cells treated with 
10 μM 4-HPR for 24 or 48 hrs. Activity was normalized to the activity in the untreated cells (control), and blocked by addition 
of 10 μM caspase-8 inhibitor (zIETD-fmk).
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resistant compared to SHEP-ncs cells, thus confirming
that 4-HPR-induced cell death requires caspase-8 expres-
sion and activation.
4-HPR enhances chemotherapeutic drug- or TRAIL-
mediated toxicity in metastatic neuroblasts
Next, we have investigated if 4-HPR could enhance drug-
mediated apoptosis in BM metastatic neuroblasts, which,
contrary to what occurs with 4-HPR, are more resistant
than PTX neuroblasts to toxicity by drugs. Indeed, we had
previously shown that BM metastatic neuroblasts are
resistant to etoposide/VP16 toxicity [22]. Figure 7A con-
firms that BM are more resistant than PTX cells to drug
toxicity after incubation of cells with 20 or 40 μM VP16
for 24 hours. PTX and BM neuroblasts were pretreated
with 2.5 μM 4-HPR for 96 hours and data show that 4-
HPR enhances VP16-mediated toxicity in BM cells (Figure
7B). These data are in accordance with a previous study
showing a synergistic apoptotic response of 4-HPR with
chemotherapeutic agents, including cisplatin, carboplatin
or etoposide in NB [31]. Caspase-8-positive NB cells have
been previously demonstrated to be weakly sensitive to
TRAIL [25]. Moreover, studies reported silencing of cas-
pase-8 expression in malignant IGR-N-91 cells as a possi-
ble mechanism of resistance to TRAIL-induced apoptosis.
Indeed, sensitivity to TRAIL was fully restored in the cas-
pase-8-complemented NB cell line [32]. Here we analyzed
the cell death response of BM cells to TRAIL-mediated tox-
icity compared with PTX cells (Figure 8A). The caspase-8-
silenced BM neuroblasts appear more resistant than PTX
neuroblasts to TRAIL-toxicity. Moreover, we observed a
more important enhancement of TRAIL-mediated toxicity
in BM cells than in PTX after incubation with 2.5 μM 4-
HPR for 96 hours (Figure 8B). These data corroborate pre-
vious studies showing that 4-HPR enhances TRAIL-medi-
ated apoptosis in ovarian or colon cancer cells [33,34].
Discussion
Numerous studies have reported that the loss of caspase-
8 expression occurs in medulloblastoma [35], colon carci-
noma [36], more frequently in small cell lung carcinoma,
glioma and malignant neuroblastoma [37,38,6]. In high-
risk neuroblastoma, resistance to apoptosis may involve
several defects of the apoptotic pathway, such as over-
expression of the anti-apoptotic proteins Bcl-2, Bcl-xL, and
survivin [39], but also deregulation of the death receptor
pathway with the inactivation of caspase-8 gene expression
mostly by gene silencing [5,6,40].
The present study shows that the downregulation of cas-
pase-8 plays a role in resistance of metastatic neuroblast-
oma to apoptosis, which could be reversed by 4-HPR
treatment. Since 4-HPR upregulates caspase-8 expression,
apoptotic resistance induced by 4-HPR appears improba-
ble. We have investigated the expression of caspase-8 in
the IGR-N-91 NB experimental model which offers the
opportunity to compare NB cell lines established from a
primary tumor and matched metastatic neuroblasts
[21,22]. In this model, the IGR-N-91 parental cell line is
negative for caspase-8 protein despite normal level of
mRNA. This suggests the occurrence of a post-transcrip-
tional mechanism to shut off caspase-8 protein expression
in parental IGR-N-91 cells. We observed that caspase-8
protein is re-expressed in the primary tumor cell line
(PTX) and both caspases-8 mRNA and protein expressions
are lost in metastatic neuroblasts (BM and Myoc). As
known and previously described [6], the role of methyla-
tion in the caspase-8 silencing process is supported by the
up-regulation of caspase-8 observed in NB cell lines
treated with demethylating agents such as 5-azacytidine.
Thus, changes in methylation and/or chromatin structure
might explain the caspase-8 silencing in NB metastatic
cells, and inversely the re-expression of caspase-8 in
tumors with the contribution of others mechanisms such
as interactions with the cellular microenvironment. More-
over, caspase-8 seems to not impact primary tumor
growth as the cells interact with each other and with the
IGR-N91 neuroblasts sensitivity to 4-HPR-induced cell deathFigure 5
IGR-N91 neuroblasts sensitivity to 4-HPR-induced 
cell death. A) The IGR-N91-M control cells and IGR-N91-
C8 clone 19 cells were treated with 2.5 or 5 μM 4HPR for 
48 hrs. Cell lysates were analyzed by IB for caspase-8, -9 and 
β-actin as loading control. B) Cell death was determined by 
the MTS assay and the data represent the mean values of two 
representative experiments ± SD. **P < 0.01 indicates differ-
ence between 4HPR-treated cells and EtOH-treated cells.
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BMC Cancer 2009, 9:97 http://www.biomedcentral.com/1471-2407/9/97remodeling tumor ECM, caspase-8 being able to regulate
tumor survival during tissue invasion [41]. The loss of cas-
pase-8 is specific since the expression of other caspases or
apoptotic partners was unchanged. Interestingly, our data
are consistent with recent findings which first, correlate
the decrease of apoptosis induction due to the loss of cas-
pase-8 with the increase of metastatic potential in NB [9],
and secondly, with the loss of caspase-8 or integrins
allowing malignant disseminated cells to acquire a greater
potential to survive [10].
As the role of caspase-8 appears to be crucial in preventing
metastasis, we therefore decided to study the effect of the
synthetic retinoid fenretinide/4-HPR on caspase-8 expres-
Caspase 8-negative SH-EP neuroblasts are resistant to 4-HPR-induced cell deathFigure 6
Caspase 8-negative SH-EP neuroblasts are resistant to 4-HPR-induced cell death. A) SH-EP cells infected with 
shRNA targeting caspase-8 (shC8) or nonsilencing control (nsc) were treated with 5, 10 or 15 μM 4-HPR for 48 hrs. Cell 
lysates were analyzed by western blotting for caspase-8 and β-actin used as loading control. B) Cell death was measured by 
MTS cell proliferation assays in the SH-EP cell lines. Mean values of three independent experiments ± SD are shown. ** P< 0.01 
indicates difference between SHEP-nsc and SHEP-shC8 cells.
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4-HPR enhances VP16-mediated cytotoxicity in BM metastatic neuroblastsFigure 7
4-HPR enhances VP16-mediated cytotoxicity in BM metastatic neuroblasts. A) PTX and BM cells were treated with 
20 or 40 μM etoposide/VP16 for 24 hrs. Cell death was measured as previously described and the data are expressed as a per-
centage of control cells. Mean ± SD of three independent experiments. **P < 0.01 indicates significant difference between PTX 
and BM cells. B) PTX and BM cells were incubated with 2.5 μM 4-HPR for 96 hrs, then with 20 μM VP16 for 24 hrs. Data 
points show mean ± SD of a representative experiment. The (*) indicates that synergism was demonstrated for VP16 and 
4HPR.
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4-HPR enhances TRAIL-mediated cytotoxicity in BM metastatic neuroblastsFigure 8
4-HPR enhances TRAIL-mediated cytotoxicity in BM metastatic neuroblasts. A) PTX and BM neuroblasts were 
incubated with increasing concentrations of TRAIL for 48 hrs, as indicated. BM cells are more resistant than PTX cells to 
TRAIL-mediated toxicity. Data points show mean ± SD of three independent experiments. B) PTX and BM cells were incu-
bated with or without 4-HPR (2.5 μM) for 96 h, and TRAIL was added to a final concentration of 250 ng/ml for the final 48 h in 
culture. Mean ± SD of three independent experiments. The (*) indicates that synergism was demonstrated at these concentra-
tions of TRAIL and 4HPR.
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shown that 4-HPR induced apoptosis through RAR-
dependent or -independent pathways [23,24]. The activa-
tion of c-Jun N-terminal kinase as well as the activation of
mitochondrial pathway via generation of reactive oxygen
species (ROS) or the induction of increased ceramide pro-
duction have been implicated in 4HPR-mediated apoptosis
[42,43]. Here, we report that 4-HPR induces apoptosis both
in PTX and BM malignant neuroblasts. Interestingly, 4-HPR
up-regulates caspase-8 expression in caspase-8 negative
IGR-N91 cells, i.e, BM neuroblasts or retrovirally-trans-
duced IGR-N91-control cells. Moreover, this up-regulation
is correlated with a significant increase of apoptotic cell
death in BM neuroblasts. Data confirm that BM metastatic
neuroblasts are more sensitive to 4-HPR-induced cell death
than PTX cells and that caspase-8 activation occurs in BM
neuroblasts treated by 4-HPR. This higher sensitivity of BM
cells to 4-HPR may be explained by two mechanisms: first,
the involvement of IMD impairment in the apoptotic
resistance of metastatic BM cells. Interestingly, we have
observed a decrease of the expression levels of the α3 and
β1 integrins in BM or Myoc metastatic cells compared with
parental IGR or PTX cells (data not shown). As 4-HPR
induces an increase of caspase-8 expression, it would be
informative to accurately investigate if 4-HPR is able to
restore IMD, i.e not only caspase-8 but also α3β1 integrin
expressions. Thus, the higher sensitivity of BM cells to 4-
HPR might be imputed to a synergistic effect of both intrin-
sic 4-HPR toxicity and restored IMD; secondly, studies
using specific inhibitors show that 4HPR-induced cell
death is almost completely inhibited by the addition of
zIETD-fmk, a caspase-8 inhibitor and more partially with
zLEHD-fmk, a caspase-9 inhibitor. In contrast, these inhib-
itors did not protect PTX cells for 4-HPR toxicity, suggesting
that cell death induced by 4-HPR occurred by distinct path-
ways in PTX cells compared to BM cells.
Previous findings reported that 4-HPR stimulates the gen-
eration of intracellular free radicals which has a causative
role in the induction of apoptosis and that caspase-3 acti-
vation is required in this oxidative stress-mediated apop-
tosis [24,44]. However, in our study, the caspase-3
inhibitor does not inhibit 4-HPR-induced apoptosis in
BM neuroblasts, suggesting that other pathways may be
involved. If 4-HPR-induced BM cell death is partially
inhibited by the caspase-2 inhibitor, further studies are
clearly needed to elucidate the mechanism of 4HPR/cas-
pases interactions involved in this experimental model.
Nevertheless, the crucial role of caspase-8 in 4-HPR medi-
ated death in BM cells is confirmed by data performed
with the transfected and silenced pair of IGR-N91-M/C8
and SH-EP-nsc/shC8 cells. As observed in the PTX/BM
pair of cells, caspase-8 expression was increased by 4-HPR
in the caspase-8 deficient cells IGR-N91-M cells, whereas
in SH-EP-shC8, caspase-8 over-expression could not be
detected because C8 mRNA was degraded by the shRNA.
Interestingly, the stable restoration of caspase-8 expres-
sion in IGR-N91-C8 cells increased their sensitivity to 4-
HPR compared to parental IGR-N91-M cells, while the
reversed experiment, performed by down-regulating cas-
pase-8 expression in SH-EP-shC8, increased their resist-
ance to 4-HPR compared to parental SH-EP-nsc.
Similar caspase-8 activation has been described in 4-HPR-
induced cell lines such as ovarian cancer cell lines or Fas-
defective hepatoma cells [33,45]. More recently, different
retinoic acid derivatives, including 4-HPR, were demon-
strated to increase caspase-8 transcription via induction of
phosphorylated CREB in NB [46]. Moreover, the authors
demonstrate that the binding of this transcription factor to
sequences within the caspase-8 gene sensitizes cells to
TNFα or drug-induced apoptosis [46]. Our study corrobo-
rates that caspase-8 appears as a key mediator of the syner-
gistic effect observed between RA derivatives/4HPR and
drugs/etoposide or TRAIL. Indeed, 4-HPR represents a
potential clinical candidate to enhance the effect of chemo-
therapy in NB [31]. However, this effect was imputed to the
generation of free radicals by 4-HPR, considered as the key
property of this retinoid leading to synergistic response
with chemotherapy [31]. Resistance to TRAIL-mediated cell
death has been attributed to deregulation of a number of
signalling molecules [47], including inactivation of cas-
pase-8 [5-7]. Indeed, restored caspase-8 expression results
in an increase of sensitivity of NB cells in TRAIL-induced
apoptosis [25]. Here, we report that the caspase-8-negative
BM neuroblasts are more resistant to TRAIL-mediated cell
death than PTX cells. Moreover, a more important enhance-
ment of TRAIL-induced cell death is observed in BM neu-
roblasts pre-treated with 4HPR. Recent studies performed
in colon cancer cell lines described such a synergistic effect
of the combination of TRAIL with 4-HPR leading to the
activation of multiple caspases [34].
Both previous reports and our study propose the restora-
tion of caspase-8 function as essential to sensitize resistant
NB to apoptosis. However, NB malignant cells are charac-
terized by a great heterogeneity and show various resistance
or sensitivity to TRAIL or drug toxicities. Thus, studies have
always to be performed to develop new and various combi-
nation regimens for high-risk neuroblastoma. Indeed, pre-
vious findings reported the caspase-8 induction by IFN-γ in
selected NB cells [12], able to sensitize NB to TRAIL apop-
tosis [48]. More recently, the association of the demethylat-
ing agent 5-Aza-2'-deoxycytidine (5-dAzaC) with IFN-γ was
described to cooperate using lower individual drug doses in
order to increase the therapeutic efficacy and decrease the
toxicity of TRAIL-apoptosis in NB [14].
Conclusion
Our study confirms that 4-HPR/Fenretinide is a very inter-
esting therapeutic drug, reported to exert a benefit effect in
the treatment of prostate cancer metastasis or to suppressPage 11 of 13
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BMC Cancer 2009, 9:97 http://www.biomedcentral.com/1471-2407/9/97the invasiveness of bone metastatic breast cancer cells
[49,50]. Of note, fenretinide is currently studied for a
phase II trial in HR-NB patients following a successful
phase I trial and recent pharmacokinetics studies con-
ducted in NB patients indicated that a continuous oral
administration of 4-HPR is preferred to maintain a rele-
vant and efficient plasma concentration of 0.7 -10 μM
range [19, 51)]. Moreover, active metabolites of 4-HPR
such as 4-oxo-4-HPR are currently under investigation
and may provide a promising therapy for HR-NB [51].
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